As of 2024-12-12, the EV/EBITDA ratio of Royalty Pharma PLC (RPRX) is 14.09. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RPRX's latest enterprise value is 21,504.67 mil USD. RPRX's TTM EBITDA according to its financial statements is 1,526.18 mil USD. Dividing these 2 quantities gives us the above RPRX EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 11.6x - 13.7x | 12.1x |
| Forward P/E multiples | 18.8x - 30.8x | 20.6x |
| Fair Price | 18.80 - 170.77 | 65.18 |
| Upside | -25.4% - 577.7% | 158.7% |
| Date | EV/EBITDA |
| 2024-12-11 | 14.09 |
| 2024-12-10 | 14.24 |
| 2024-12-09 | 14.40 |
| 2024-12-06 | 14.36 |
| 2024-12-05 | 14.55 |
| 2024-12-04 | 14.44 |
| 2024-12-03 | 14.53 |
| 2024-12-02 | 14.57 |
| 2024-11-29 | 14.65 |
| 2024-11-27 | 14.63 |
| 2024-11-26 | 14.51 |
| 2024-11-25 | 14.58 |
| 2024-11-22 | 14.57 |
| 2024-11-21 | 14.55 |
| 2024-11-20 | 14.48 |
| 2024-11-19 | 14.40 |
| 2024-11-18 | 14.32 |
| 2024-11-15 | 14.28 |
| 2024-11-14 | 14.24 |
| 2024-11-13 | 14.34 |
| 2024-11-12 | 14.40 |
| 2024-11-11 | 14.54 |
| 2024-11-08 | 14.48 |
| 2024-11-07 | 14.60 |
| 2024-11-06 | 14.65 |
| 2024-11-05 | 14.99 |
| 2024-11-04 | 14.86 |
| 2024-11-01 | 14.82 |
| 2024-10-31 | 14.79 |
| 2024-10-30 | 14.86 |
| 2024-10-29 | 14.84 |
| 2024-10-28 | 14.89 |
| 2024-10-25 | 14.77 |
| 2024-10-24 | 14.89 |
| 2024-10-23 | 14.92 |
| 2024-10-22 | 14.93 |
| 2024-10-21 | 15.07 |
| 2024-10-18 | 15.16 |
| 2024-10-17 | 15.19 |
| 2024-10-16 | 15.26 |
| 2024-10-15 | 15.11 |
| 2024-10-14 | 15.12 |
| 2024-10-11 | 15.18 |
| 2024-10-10 | 14.97 |
| 2024-10-09 | 15.01 |
| 2024-10-08 | 14.92 |
| 2024-10-07 | 15.01 |
| 2024-10-04 | 15.07 |
| 2024-10-03 | 15.07 |
| 2024-10-02 | 15.26 |